141 related articles for article (PubMed ID: 37074146)
1. Epidemiological and clinical features, therapeutic strategies and outcomes in patients with hyperhaemolysis: A systematic review.
Jacobs JW; Stephens LD; Allen ES; Binns TC; Booth GS; Hendrickson JE; Karafin MS; Tormey CA; Woo JS; Adkins BD
Br J Haematol; 2023 Jun; 201(6):1025-1032. PubMed ID: 37074146
[TBL] [Abstract][Full Text] [Related]
2. Post-transfusion hyperhaemolysis in a patient with sickle cell disease: use of steroids and intravenous immunoglobulin to prevent further red cell destruction.
Cullis JO; Win N; Dudley JM; Kaye T
Vox Sang; 1995; 69(4):355-7. PubMed ID: 8751307
[TBL] [Abstract][Full Text] [Related]
3. Hyperhaemolysis caused by anti-HI antibodies in a patient with myelodysplastic syndrome following a first ever red cell transfusion.
Hinton R; Haji R; Kaczmarski R; Layton M; Danga A
Transfus Med; 2023 Aug; 33(4):349-351. PubMed ID: 37186414
[TBL] [Abstract][Full Text] [Related]
4. How we treat delayed haemolytic transfusion reactions in patients with sickle cell disease.
Gardner K; Hoppe C; Mijovic A; Thein SL
Br J Haematol; 2015 Sep; 170(6):745-56. PubMed ID: 25967919
[TBL] [Abstract][Full Text] [Related]
5. Hyperhaemolytic Syndrome in Sickle Cell Disease: Clearing the Cobwebs.
Madu AJ; Ugwu AO; Efobi C
Med Princ Pract; 2021; 30(3):236-243. PubMed ID: 33176303
[TBL] [Abstract][Full Text] [Related]
6. Posttransfusion hyperhemolysis is arrested by targeting macrophage activation with novel use of Tocilizumab.
Lee LE; Beeler BW; Graham BC; Cap AP; Win N; Chen F
Transfusion; 2020 Jan; 60(1):30-35. PubMed ID: 31642065
[TBL] [Abstract][Full Text] [Related]
7. Delayed haemolytic transfusion reaction in adults with sickle cell disease: a 5-year experience.
Vidler JB; Gardner K; Amenyah K; Mijovic A; Thein SL
Br J Haematol; 2015 Jun; 169(5):746-53. PubMed ID: 25753472
[TBL] [Abstract][Full Text] [Related]
8. Preoperative blood transfusions for sickle cell disease.
Estcourt LJ; Kimber C; Trivella M; Doree C; Hopewell S
Cochrane Database Syst Rev; 2020 Jul; 7(7):CD003149. PubMed ID: 32614473
[TBL] [Abstract][Full Text] [Related]
9. Delayed haemolytic transfusion reaction and hyperhaemolysis complicating peri-operative blood transfusion in sickle cell disease.
McGlennan AP; Grundy EM
Anaesthesia; 2005 Jun; 60(6):609-12. PubMed ID: 15918834
[TBL] [Abstract][Full Text] [Related]
10. Histopathological evidence for macrophage activation driving post-transfusion hyperhaemolysis syndrome.
Win N; Lucas S; Hebballi S; McKernan A; Hamilton R; Robinson I; Chen F
Br J Haematol; 2019 Aug; 186(3):499-502. PubMed ID: 31020643
[TBL] [Abstract][Full Text] [Related]
11. Utility of hemoglobin electrophoresis to distinguish between severe delayed hemolytic transfusion reaction versus hyperhemolysis syndrome.
Lukin R; Law JY; Lokhandwala PM
Transfus Apher Sci; 2024 Jun; 63(3):103919. PubMed ID: 38582651
[TBL] [Abstract][Full Text] [Related]
12. Delayed hemolytic transfusion reaction/hyperhemolysis syndrome in children with sickle cell disease.
Talano JA; Hillery CA; Gottschall JL; Baylerian DM; Scott JP
Pediatrics; 2003 Jun; 111(6 Pt 1):e661-5. PubMed ID: 12777582
[TBL] [Abstract][Full Text] [Related]
13. A case of hyperhaemolysis syndrome in a pregnant Chinese woman with β-thalassemia during perinatal transfusion.
Wu Y; Ji Y; Dai B; Guo F; Wu Y; He Z; Mo C; Wu S; Hu Y
Transfus Med; 2021 Feb; 31(1):24-29. PubMed ID: 33331032
[TBL] [Abstract][Full Text] [Related]
14. A case of hyperhemolysis syndrome in sickle cell disease and concomitant COVID-19.
Green A; Jones H; Nero A; Ibrahim IF; Sarode R; Scheid LM; Webb CB; Adkins BD; Yates SG
Transfus Apher Sci; 2023 Aug; 62(4):103712. PubMed ID: 37149492
[TBL] [Abstract][Full Text] [Related]
15. Abnormality of erythrocyte membrane n-3 long chain polyunsaturated fatty acids in sickle cell haemoglobin C (HbSC) disease is not as remarkable as in sickle cell anaemia (HbSS).
Ren H; Ghebremeskel K; Okpala I; Ugochukwu CC; Crawford M; Ibegbulam O
Prostaglandins Leukot Essent Fatty Acids; 2006 Jan; 74(1):1-6. PubMed ID: 16314081
[TBL] [Abstract][Full Text] [Related]
16. Transfusion support for haemoglobinopathies.
Greenwalt TJ; Zelenski KR
Clin Haematol; 1984 Feb; 13(1):151-65. PubMed ID: 6373080
[TBL] [Abstract][Full Text] [Related]
17. Hyperhemolysis in a patient with sickle cell disease and recent SARS-CoV-2 infection, with complex auto- and alloantibody work-up, successfully treated with tocilizumab.
Fuja C; Kothary V; Carll TC; Singh S; Mansfield P; Wool GD
Transfusion; 2022 Jul; 62(7):1446-1451. PubMed ID: 35588309
[TBL] [Abstract][Full Text] [Related]
18. Hydroxyurea (hydroxycarbamide) for sickle cell disease.
Nevitt SJ; Jones AP; Howard J
Cochrane Database Syst Rev; 2017 Apr; 4(4):CD002202. PubMed ID: 28426137
[TBL] [Abstract][Full Text] [Related]
19. Prophylactic versus selective blood transfusion for sickle cell disease in pregnancy.
Okusanya BO; Oladapo OT
Cochrane Database Syst Rev; 2013 Dec; (12):CD010378. PubMed ID: 24297507
[TBL] [Abstract][Full Text] [Related]
20. Fatal Delayed Haemolytic Transfusion Reaction and Hyperhaemolysis Syndrome in a Pregnant Woman with Sickle Cell Anaemia.
Asnawi AW; Sathar J; Mohamed R; Deraman R; Kumaran S; Hamid SS; Zakaria MZ
Indian J Hematol Blood Transfus; 2016 Jun; 32(Suppl 1):251-3. PubMed ID: 27408406
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
